Search Result

Results for "

P2Y12

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Arrestin (1) Cytochrome P450 (3) Drug Metabolite (3) Isotope-Labeled Compounds (2) P2Y Receptor (30)
By Research Areas:	Cancer (6) Cardiovascular Disease (25) Inflammation/Immunology (3) Neurological Disease (1)

Inhibitors & Agonists

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149454

*P2Y1/P2Y12* antagonist-1**	P2Y Receptor	Cancer
P2Y1/P2Y12 antagonist-1 (compound 24w) is an orally available dual inhibitor of *P2Y1* and *P2Y12* with antiplatelet activity. P2Y1/P2Y12 antagonist-1 inhibits ADP-induced platelet aggregation in rabbit plasma with an IC₅₀ of 4.23 μM. P2Y1/P2Y12 antagonist-1 exhibits potent inhibitory effects in rat thrombosis model.

HY-108660

PSB-0739	P2Y Receptor	Cardiovascular Disease
PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y₁₂ receptor antagonist with a K_i values of 24.9 nM. The P2Y₁₂ receptor plays a crucial role in platelet aggregation. Antithrombotic effect .

HY-125989

2-Methylthio-AMP 1 Publications Verification 2-MeSAMP; 2-Methylthioadenosine 5′-monophosphate; 2-Methylthioadenosine 5′-phosphate	P2Y Receptor	Cardiovascular Disease
2-Methylthio-AMP (2-MeSAMP) is a selective and direct *P2Y₁₂* antagonist. 2-Methylthio-AMP is an inhibitor of ADP-dependent platelet aggregation .

HY-123669

R-138727	P2Y Receptor	Cardiovascular Disease
R-138727, the thiol-containing active metabolite of Prasugrel, is an irreversible platelet P2Y12 receptor inhibitor. R-138727 inhibits ADP-induced platelet aggregation .

HY-125989B

2-Methylthio-AMP diTEA 2-MeSAMP diTEA; 2-Methylthioadenosine 5′-monophosphate diTEA; 2-Methylthioadenosine 5′-phosphate diTEA	P2Y Receptor	Cardiovascular Disease
2-Methylthio-AMP (2-MeSAMP) diTEA is a selective and direct *P2Y₁₂* antagonist. 2-Methylthio-AMP diTEA is an inhibitor of ADP-dependent platelet aggregation .

HY-10064

Ticagrelor 4 Publications Verification AZD6140; AR-C 126532XX	P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor (AZD6140) is a reversible oral *P2Y12* receptor antagonist for the treatment of platelet aggregation.

HY-136501

MRS2395	P2Y Receptor	Cardiovascular Disease
MRS2395, an dipivaloyl derivative, is a potent *P2Y12* receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a K_i of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC₅₀ of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6 .

HY-109122

Selatogrel ACT-246475	P2Y Receptor	Cardiovascular Disease
Selatogrel (ACT-246475) is a reversible and selective *P2Y₁₂* receptor antagonist which inhibits platelet aggregation with an IC₅₀ of 8 nM. Selatogrel exhibits antithrombotic efficacy .

HY-15283

Clopidogrel Maximum Cited Publications 17 Publications Verification Clopidogrelum	P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel is an orally active platelet inhibitor that targets *P2Y12* receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

HY-15284

Prasugrel PCR 4099	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284A

Prasugrel hydrochloride PCR 4099 hydrochloride	P2Y Receptor	Cardiovascular Disease
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-10064S

Ticagrelor-d7	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor-d₇ is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation[1][2].

HY-15284B

Prasugrel (Maleic acid) PCR 4099 (Maleic acid)	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-11021

Elinogrel PRT060128	P2Y Receptor	Cardiovascular Disease
Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet *P2Y₁₂* antagonist (IC₅₀=20 nM). It is orally and intravenously available and has potent antiplatelet effects .

HY-15876

Clopidogrel thiolactone	Drug Metabolite P2Y Receptor	Cardiovascular Disease
Clopidogrel thiolactone is an important intermediate in the metabolism of clopidogrel (HY-15283). Clopidogrel thiolactone has antiplatelet aggregatione effects. Clopidogrel is a P2Y12 receptor inhibitor that exerts antiplatelet effects .

HY-133781

cis-Clopidogrel-MP derivative Clopidogrel-MP-AM	Drug Metabolite	Others
cis-Clopidogrel-MP derivative (Clopidogrel-MP-AM) is a 3’-methoxyacetophenone derivative of Clopidogrel active metabolite . Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor .

HY-136142

Prasugrel chloride impurity	Drug Metabolite	Others
Prasugrel chloride impurity is a catp impurity of Prasugrel, exacted from patent US20130345428A1, line 0053. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15799

AZD1283	P2Y Receptor	Cardiovascular Disease
AZD1283 is a potent P2Y₁₂ receptor antagonist with a binding IC₅₀ of 11 nM and a GTPγS IC₅₀ of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .

HY-15284S1

Prasugrel-d3 PCR 4099-d₃	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

HY-118284

Vicagrel 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .

HY-15284S

Prasugrel-d5 PCR 4099-d₅	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

HY-15284S2

Prasugrel-d4 PCR 4099-d₄	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₄ is the deuterium labeled Prasugrel[1]. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[2].

HY-15284R

Prasugrel (Standard) PCR 4099 (Standard)	P2Y Receptor	Cardiovascular Disease
Prasugrel (Standard) is the analytical standard of Prasugrel. This product is intended for research and analytical applications. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-19638A

Cangrelor tetrasodium 1 Publications Verification AR-C69931MX tetrasodium	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet *P2Y12* antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .

HY-17459

Clopidogrel hydrogen sulfate Maximum Cited Publications 17 Publications Verification (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-19638

Cangrelor AR-C69931MX
Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet *P2Y12* antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .

HY-17459S

Clopidogrel-d3 hydrogen sulfate (S)-(+)-Clopidogrel bisulfate-d₃; (S)-(+)-Clopidogrel-d₃ hydrogen sulfate	P2Y Receptor Cytochrome P450
Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

HY-17459R

Clopidogrel hydrogen sulfate (Standard) (S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-111755

Oral antiplatelet agent 1	P2Y Receptor	Cardiovascular Disease
Oral antiplatelet agent 1 is a potent P2Y₁₂ receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC₅₀ value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .

HY-110322A

PPTN	P2Y Receptor	Inflammation/Immunology
PPTN is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a K_B value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .

HY-110322

PPTN hydrochloride 1 Publications Verification	P2Y Receptor	Inflammation/Immunology
PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a K_B value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity .

HY-108656

MRS2365	P2Y Receptor Arrestin	Cardiovascular Disease
MRS2365 is a potent and selective P2Y1 receptor (EC₅₀=0.4 nM) /[ ³⁵S]GTPγS binding/β-arrestin 2 recruitment agonist with an EC₅₀ of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors .

HY-108648

2-Methylthioadenosine diphosphate trisodium 2-Methylthio-ADP trisodium	P2Y Receptor	Neurological Disease
2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC₅₀s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC₅₀s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1 .

Species:	Human (1) Mouse (1)
Tag:	His (2)
Source:	E. coli Cell-free (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P702411

	P2RY12 Protein, Mouse (Cell-Free, His) P2Y purinoceptor 12; P2Y12	Mouse	E. coli Cell-free
	P2RY12 protein is a receptor for ADP and ATP and inhibits adenylyl cyclase second messenger system through G protein. P2RY12 is critical for normal platelet aggregation and coagulation, where it mediates responses to nucleotide signals. P2RY12 Protein, Mouse (Cell-Free, His) is the recombinant mouse-derived P2RY12 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of P2RY12 Protein, Mouse (Cell-Free, His) is 347 a.a., with molecular weight of 45.5 kDa.

HY-P702410

	P2RY12 Protein, Human (Cell-Free, His) P2Y purinoceptor 12; ADP-glucose receptor; ADPG-R; P2T(AC); P2Y(AC); P2Y(cyc); P2Y12 platelet ADP receptor; P2Y(ADP); SP1999	Human	E. coli Cell-free
	P2RY12 Protein, a receptor for adenosine diphosphate (ADP) and adenosine triphosphate (ATP), inhibits the adenylyl cyclase second messenger system via G-proteins. Unlike uridine diphosphate (UDP) and uridine triphosphate (UTP), P2RY12 crucially regulates platelet aggregation and blood coagulation, serving as a key regulator in these physiological processes. P2RY12 Protein, Human (Cell-Free, His) is the recombinant human-derived P2RY12 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of P2RY12 Protein, Human (Cell-Free, His) is 342 a.a., with molecular weight of 42.2 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Prasugrel-d3
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

Ticagrelor-d7
Ticagrelor-d₇ is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation[1][2].

Prasugrel-d5
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

Prasugrel-d4
Prasugrel-d₄ is the deuterium labeled Prasugrel[1]. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[2].

Clopidogrel-d3 hydrogen sulfate
Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: